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Dendritic cells (DCs) play a crucial role in initiating and shaping immune responses. The
effects of DCs on adaptive immune responses depend partly on functional specialization
of distinct DC subsets, and partly on the activation state of DCs, which is largely dictated
by environmental signals. Fully activated immunostimulatory DCs express high levels
of costimulatory molecules, produce pro-inflammatory cytokines, and stimulate T cell
proliferation, whereas tolerogenic DCs express low levels of costimulatory molecules,
produce immunomodulatory cytokines and impair T cell proliferation. Relevant to the
increasing use of immune checkpoint blockade in cancer treatment, signals generated
from inhibitory checkpoint molecules on DC surface may also contribute to the inhibitory
properties of tolerogenic DCs. Yet, our knowledge on the expression of inhibitory
molecules on human DC subsets is fragmentary. Therefore, in this study, we investigated
the expression of three immune checkpoints on peripheral blood DC subsets, in basal
conditions and upon exposure to pro-inflammatory and anti-inflammatory stimuli, by
using a flow cytometric panel that allows a direct comparison of the activatory/inhibitory
phenotype of DC-lineage and inflammatory DC subsets. We demonstrated that
functionally distinct DC subsets are characterized by differential expression of activatory
and inhibitory molecules, and that cDC1s in particular are endowed with a unique
immune checkpoint repertoire characterized by high TIM-3 expression, scarce PD-L1
expression and lack of ILT2. Notably, this unique cDC1 repertoire was subverted in
a group of patients with myelodysplastic syndromes included in the study. Applied to
the characterization of DCs in the tumor microenvironment, this panel has the potential
to provide valuable information to be used for investigating the role of DC subsets in
cancer, guiding DC-targeting treatments, and possibly identifying predictive biomarkers
for clinical response to cancer immunotherapy.
Keywords: plasmacytoid dendritic cells, conventional cDC1 dendritic cells, conventional cDC2 dendritic cells,
PD-L1, ILT2, TIM-3, immune checkpoint, myelodysplastic syndromes
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INTRODUCTION
Dendritic cells (DCs) are the single most central players in all
immune responses. They are ubiquitous professional antigen-
presenting cells that have a crucial role in initiating and
shaping immune responses. Human DCs can be subdivided
in different subsets that differ from each other in their
origin, growth factor requirements, migration patterns, and
specialized immunological functions. Under non-inflammatory
conditions, bone marrow-derived DC progenitors give rise to
developmentally distinct DC subsets that can be identified on
a transcriptomic and phenotypic basis and that consist of two
subsets of conventional (or myeloid) DCs (cDCs) and one
subset of plasmacytoid DCs (pDCs) (1–3). cDCs express myeloid
markers including CD11c, and are the most important antigen
presenting cells to T lymphocytes. Through the expression of
pathogen recognition receptors and cytokine receptors, cDCs
can be activated differentially by distinct signals coming from
microbes, dying cells and immune cells. Type 1 cDCs (cDC1s)
require the transcription factors IRF8, BATF3, and ID2 for
their development (4), and express CD141 (BDCA-3) and other
markers on their surface (1, 4, 5). They play a crucial role in
immune responses against intracellular pathogens and cancer,
mainly related to their intrinsic ability to efficiently up-take and
cross-present antigens, and to activate T helper 1 (Th1) and
cytotoxic T cell responses (4, 6, 7). cDC1s isolated from human
lung have also been demonstrated to efficiently activate Th2
polarization (5). Type 2 cDCs (cDC2s) require the transcription
factors IRF4, IRF2, and Traf6 for their development (4), and
express CD1c (BDCA-1) and other markers on their surface
(1, 7). Molecularly equipped to generate Th17 responses (8),
cDC2s promote immune responses against extracellular bacteria
and fungi (4). Moreover, unlike murine cells, human cDC2s have
also been demonstrated to cross-present antigens and produce
IL-12 upon proper stimulation, thus sharing with cDC1s the
ability to activate cytotoxic and Th1 immune responses in some
specific conditions (7, 9, 10). pDCs lack myeloid markers, while
express CD123 (IL-3 receptor α-chain) and other pDC-restricted
markers, such as CD303 (BDCA-2) and CD304 (BDCA-4). They
are unique in their ability to rapidly produce type I IFN upon
viral infections, property that confers these cells a primary
role in anti-viral defenses (11). Upon opportune stimulation,
pDCs can also cross-present antigens and promote other
inflammatory responses, supporting a multifaceted function of
this DC subset in the activation of adaptive immune responses
(9, 11, 12). Upon inflammatory conditions, additional subsets
of inflammatory DCs can infiltrate the site of inflammation.
Although their ontology is difficult to address in humans,
transcriptomic analyses suggest that inflammatory DCs derive
from monocytes rather than from DC precursors (7, 13, 14),
monocyte differentiation into monocyte-derived DCs (moDCs)
being driven by the activation of the aryl hydrocarbon receptor
(15). moDCs are present in many different human steady-state
tissues, and their number rapidly increases upon inflammation
[reviewed in (7)]. Despite great phenotypic heterogeneity among
moDCs obtained from different anatomic sites, tissue-resident
moDCs usually express CD1a (7, 16, 17). Inflammatory DCs
also include a small population of 6-sulfo-LacNAc (slan)-positive
cells (2, 7). Although slanDCs circulating in the blood have a
transcriptional profile that overlap with the profile of CD16+
non-classical monocytes thus suggesting a monocyte origin of
these cells (2, 18), slanDCs in peripheral tissues are endowed
with DC functions including efficient antigen presentation,
ability to activate naive T cells and promote Th1/Th17 immune
responses (19, 20).
Notably, despite the existence of a functional specialization
of distinct DC subsets, the effects of DCs on adaptive immune
responses partly depend on the subset they belong to, and partly
depend on the functional state of DCs, which is largely dictated
by environmental signals. In particular, depending on the signals
received from the microenvironment, DCs can either activate
adaptive immune responses or mediate immune tolerance
(21). Immunogenic DCs are characterized by high expression
of costimulatory molecules, production of pro-inflammatory
cytokines, and ability to stimulate T cell proliferation, whereas
tolerogenic DCs express low levels of costimulatory molecules,
produce immunomodulatory cytokines, and impair T cell
proliferation (22). Signals coming from inhibitory receptors
expressed on DC surface may also contribute to the tolerogenic
behavior of DCs, but our knowledge on this possible pathway in
regulating the activity of DCs is scarce at the moment.
The introduction of immune checkpoint inhibitors in
cancer immunotherapy has recently revolutionized cancer
treatment, providing unprecedented clinical benefits (23).
Immune checkpoints are proteins that restrict physiologic
immune cell responses in order tomaintain immune homeostasis
and protect host tissues from unnecessary damage due to
excessive inflammation (24). Although at present the efficacy of
immune checkpoints inhibitors is well-established in oncology,
there is increasing evidence that their use may also be effective in
several non-cancer acute and chronic inflammatory conditions,
including sepsis, burns, and chronic infections (25). Moreover,
innovative strategies aimed at enhancing the signaling of immune
checkpoints in autoimmune diseases are under investigation
(26). Understanding whether DC function is regulated by signals
generated from immune checkpoints expressed on DC surface
will help to understand whether the clinical efficacy of immune
checkpoint inhibitors may rely to some extent on their effects on
DCs. As the knowledge on the expression of immune checkpoints
on human DCs is only fragmentary at present, mapping the
expression of these inhibitory molecules on DC subsets at rest
and upon exposure to different conditions represents the first step
in this direction.
Therefore, in this study we investigated the expression
of three immune checkpoints, namely programmed death-
ligand 1 (PD-L1), immunoglobulin-like transcript 2 (ILT2),
and T cell immunoglobulin and mucin domain-3 (TIM-3)
on peripheral blood DC subsets, in basal conditions and
upon exposure to pro-inflammatory and anti-inflammatory
stimuli. To this aim, we developed a flow cytometric panel
that allows to identify in a single tube cDC1s, cDC2s, pDCs,
moDCs, and slanDCs, and to assess their expression of up
to six surface molecules. In order to provide a profile of the
activatory/tolerogenic phenotype of DC subsets, we included
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in our analysis the expression of three main costimulatory
molecules, namely CD40, CD80, and CD86. We applied this
tube to the analysis of whole blood samples stimulated with
the TLR4-ligand lipopolysaccharide (LPS), the TLR7-ligand
imiquimod (IMQ) and the immunosuppressive cytokine IL-10,
either alone or in combination. After proving the reliability of
our assay by confirming some previous observations regarding
the expression of costimulatory molecules on peripheral
blood DCs, we demonstrated important differences in the
expression of immune checkpoints among DC subsets that
may bring novel insights into the comprehension of DC
heterogeneity and the differential mechanisms used by DC
subsets to control immune responses. In order to test the
newly developed panel with the characterization of DCs
in a pathologic context, we further applied our 18-color
method to the study of peripheral blood DCs in patients
affected by myelodysplastic syndromes (MDS), a heterogeneous
group of haematopoietic neoplasms characterized by ineffective
haemopoiesis and progression to acute myeloid leukemia in a
third of patients (27). Our results highlighted, indeed, important
numerical and immunophenotypic changes of DC subsets in
these patients.
MATERIALS AND METHODS
Subjects
Peripheral blood was obtained by venipuncture from 16 healthy
volunteers (9 females, 7 males, mean age 39 years, range
24–62) and was anti-coagulated with sodium heparin. Ten
patients with MDS whose clinical features are reported in
Table 1 were also enrolled. Patients receiving chemotherapy,
hypomethylating agents, or luspatercept were excluded. The
study protocol was approved by the institutional review
boards (IRB) of Humanitas Research Hospital (ONC-OSS-04-
2017; 29/18). Written informed consents were provided by all
participants before inclusion in the study in compliance with the
Declaration of Helsinki.
Stimulation of WB Samples With
TLR-Ligands and IL-10
Whole blood (WB) stimulation with TLR-ligands was performed
as previously described (28). Briefly, WB samples diluted v/v
in RPMI 1640 medium (Euroclone, Wetherby, West York, UK)
were incubated at 37◦C in a 5% CO2 humidified atmosphere
for 5 h in the absence or presence of either LPS (serotype
055:B5; 100 ng/ml; Sigma Chemicals Co.) or IMQ (10µg/ml;
InvivoGen, San Diego, CA), both prepared according to the
manufacturer’s recommendations. The concentrations of LPS
and IMQ as well as the duration of cultures were established
based on previous studies (29–34). Incubation with IL-10
was performed by adding IL-10 (recombinant human IL-
10; 40 ng/ml; Peprotech, London, UK) either alone or in
combination with LPS or IMQ.
Sample Staining
At the end of the culture, WB samples (500 µl) were stained
with an 18-color flow cytometry panel of monoclonal antibodies
TABLE 1 | Clinical features of MDS patients (n = 10).
Age, years (mean, range) 72 (42–92)
Sex, males:females (n) 5:5
Hemoglobin (n)
<10.0 g/dl 7
≥10.0 g/dl 3
Neutrophil Count (n)
<1.8 × 109/L 4
≥1.8 × 109/L 6
Platelet Count (n)
<100 × 109/L 4
≥100 × 109/L 6
Transfusion Dependency (n)
Yes 5
No 5
WHO Classification (n)
AML secondary to MDS 1
MDS-RS-MLD 1
MDS-MLD 2
MDS-RS-SLD 3
MDS-SLD 1
MDS-EB-1 1
MDS-EB-2 1
Bone Marrow Fibrosis (n)
Yes 1
No 9
Bone Marrow Blasts (n)
<5% 7
≥5 to <10% 1
≥10% 2
IPSS Risk Score (n)
Low 6
int-1 2
High 1
IPSS-R Risk Score (n)
Very low 1
Low 6
Int 1
Very high 1
Therapy at Blood Withdrawal
Erythropoietin 2
(mAbs) as described below. Briefly, samples were incubated
with ammonium chloride for 10min to lyse erythrocytes. After
washing, they were stained with the Fixable Viability Stain 780
(BD Biosciences), then washed and stained with the combination
of mAbs listed in Table 2. mAbs specific for lineage markers,
HLA-DR, CD123, CD11c, CD1c, CD141, CD1a, M-DC8 (anti-
slan) were used to gate on DC subsets, while the other
mAbs were used to assess the immunostimulatory/regulatory
phenotype of each DC subset. Staining conditions for each
mAb were preliminarily determined in titration assays, as
previously described (35). All operations were done at 4◦C in
the dark.
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TABLE 2 | List of monoclonal antibodies used in this study.
Marker Description Clone Conjugate Manufacturer Batch Titer (µl)*
CD45 Leukocyte common antigen HI30 AF700 BD Biosciences 8186553 1.25
CD3 Lineage marker—T cells HIT3A FITC Biolegend B218086 1.25
CD19 Lineage marker—B cells 4G7 FITC BD Biosciences 8162764 2.5
CD20 Lineage marker—B cells 2H7 FITC BD Biosciences 3291707 2.5
CD56 Lineage marker—NK cells NCAM 16.2 FITC BD Biosciences 61126 0.3
CD14 Lineage
marker—monocytes
M5E2 BV570 Biolegend B225361 1.25
CD16 Lineage marker—NK cells
and granulocytes
3G8 BUV496 BD Biosciences 8116651 0.6
HLA-DR Major histocompatibility
complex class II molecule
G46-6 BUV661 BD Biosciences 7249926 0.15
CD123 pDC marker 7G3 PE-Cy7 BD Biosciences 8060955 0.6
CD11c mDC marker B-ly6 PE-Cy5 BD Biosciences 80859 1.25
CD141 (BDCA-3) cDC1 marker M80 BV605 Biolegend B239279 1.25
CD1c (BDCA-1) cDC2 marker L161 BV421 Biolegend B227045 1.25
M-DC8 (anti-slan) slanDC marker DD-1 APC Milteny Biotec 5180403606 5
CD1a moDC marker HI149 BUV395 BD Biosciences 7227951 0.6
CD40 Costimulatory molecule 5C3 BV650 BD Biosciences 8163659 0.6
CD80 Costimulatory molecule L307 BV510 BD Biosciences 8228546 0.3
CD86 Costimulatory molecule 2331 BUV737 BD Biosciences 7240739 0.6
CD274 (PD-L1) Inhibitory molecule MIH1 PE-CF594 BD Biosciences 7191550 2.5
CD85j (ILT2) Inhibitory molecule GHI/75 PE Biolegend B222938 2.5
CD366 (TIM-3) Inhibitory molecule 7D3 BV711 BD Biosciences 7348783 0.3
Fixable Viability Stain 780 Viability marker APC-Cy7 BD Biosciences 6174894 0.025
*staining in 100 µl.
Flow Cytometry Data Acquisition and
Analysis
All data were acquired on a FACS Symphony A5 flow cytometer
(BD Biosciences) equipped with five lasers (UV, 350 nm; violet,
405 nm; blue, 488 nm; yellow/green, 561 nm; red, 640 nm; all
tuned at 100 mW, except UV tuned at 60 mW). Flow Cytometry
Standard (FCS) 3.0 files were imported into FlowJo software
version 9.9.6 (FlowJo LLC, Ashland, Oregon), and data were
compensated by using single-stained antibody-capture beads
(CompBeads, BD Biosciences), as previously described (36).
Flow cytometry data were analyzed by standard gating to
remove aggregates and dead cells. The gating strategy used to
define DC subsets is shown in Figure 1. Because peripheral
blood DCs are characterized by forward scatter (FSc) similar
to monocytes and side scatter (SSc) similar to lymphocytes,
an acquisition gate was established based on FSc and SSc
that included both lymphocytes and monocytes (mononuclear
cells) but excluded most granulocytes and debris. DC-lineage
DCs were defined as cells negative for lineage markers (lin:
CD3, CD19, CD20, CD56), CD14 and CD16, and positive
for HLA-DR expression. Gated on these cells, pDCs and
cDCs were identified based on the expression of CD123 and
CD11c, respectively. Within cDCs, cDC1s, and cDC2s were
further identified based on the expression of CD141 and CD1c,
respectively. Because inflammatory DCs can express CD14 and
CD16, these two markers were considered separately from the
pool of the other lineage markers, and inflammatory DCs were
identified gated on cells that were negative for CD3, CD19,
CD20, and CD56, but that could be negative or positive for
CD14 and CD16. Inflammatory DCs were further identified
as being positive for the expression of HLA-DR and CD11c.
Gated on these cells, slanDCs were identified based on M-DC8
expression, moDCs based on CD1a expression. The expression
of the costimulatory molecules CD40, CD80 and CD86, and
the inhibitory molecules PD-L1, ILT2, and TIM-3 was analyzed
gated on each DC subset. Fluorescence Minus One (FMO)
controls for each of these molecules were performed. Data were
expressed as net mean fluorescence intensity (MFI), calculated
by subtracting the respective FMO’s MFI from the sample’s
MFI (37).
tSNE-Based Unsupervised Analysis
t-distributed stochastic neighbor embedding (tSNE) analysis was
performed as previously described (38). In particular, a unique
computational barcode was assigned to single samples. For each
sample, events gated on live CD45+/lin−/HLA-DR+ cells were
subsequently concatenated and visualized with tSNE (Barnes-
Hut implementation; iterations, 800; perplexity, 20; initialization,
deterministic; theta, 0.5; eta: 200). The expression of the following
markers was considered: CD14, CD16, HLA-DR, CD11c, CD123,
CD141, CD1c, M-DC8, CD1a, CD40, CD80, CD86, PD-L1,
ILT2, TIM-3.
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FIGURE 1 | Gating strategy used for the identification of 5 distinct DC subsets in the peripheral blood of healthy donors. DCs were analyzed within the gate of single
viable mononuclear cells. Lineage-DCs were identified in the gate of lin−/CD14−/CD16−/HLA-DR+ cells. Within lineage-DCs, pDCs (CD123+/CD11c−), cDC1s
(CD123−/CD11c+/CD141+) and cDC2s (CD123−/CD11c+/CD1c+) were identified. Inflammatory DCs were identified as lin−/HLA-DR+/CD11c+ that could be
negative or positive for CD14 and CD16. Within inflammatory DCs, slanDCs, and moDCs were identified based on positive staining of M-DC8 and CD1a, respectively.
As expected, moDCs were undetectable in most samples.
Statistical Analysis
Data were shown as mean ± standard error of the mean.
Paired t-test was used for comparison between DC subsets,
and to assess the effects of treatment within each subset.
Unpaired t-test was used for comparison between MDS
patients and healthy donors. All statistical analyses assumed
a two-sided significance level of 0.05. Statistical analyses were
performed using GraphPad Prism version 7 (GraphPad Software,
La Jolla, CA).
RESULTS
The New 18-Color Flow Cytometric
Method Allows the Identification of
DC-Lineage and Inflammatory DC Subsets
in Healthy Donors at Expected Rates
By applying our new DC-dedicated 18-color panel to the
analysis of DC subsets in whole blood samples obtained from
healthy donors, we observed that the frequency of pDCs in
mononuclear cells was 0.44 ± 0.06 and the frequency of
total DC-lineage cDCs was 0.79 ± 0.08. Further distinguishing
between cDC subsets, we observed that the frequency of
cDC1s and cDC2s in mononuclear cells were 0.02 ± 0.005
and 0.49 ± 0.03, respectively. Within inflammatory DCs, the
frequency of slanDCs in mononuclear cells was 0.07 ± 0.03,
while moDCs were almost undetectable in all WB samples, as
expected. All together, the frequencies of all DC subsets in the
mononuclear cell population were similar to values reported
in previous studies by us and other Authors (10, 20, 29,
30, 32, 39–41), thus indicating that the newly developed 18-
color panel allowed a reliable identification of the investigated
DC subsets.
Expression of Costimulatory and Inhibitory
Molecules on DC Subsets From Healthy
Donors in Basal Conditions
The activation state of eachDC subset in unstimulated conditions
was assessed as the surface expression of the costimulatory
molecules CD40, CD80, and CD86; their potentially regulatory
function as the surface expression of the inhibitory molecules
PD-L1, ILT2, and TIM-3. The intensity of expression of each of
these molecules was simultaneously analyzed in the gate of pDCs,
cDC1s, cDC2s, and slanDCs in the same tube, thus allowing a
direct comparison between subsets. The expression on moDCs
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FIGURE 2 | Analysis of costimulatory and inhibitory molecule expression on DC subsets. The expression of 3 costimulatory molecules (CD40, CD80, and CD86) and
3 inhibitory molecules (PD-L1, ILT2, and TIM-3) was analyzed on pDCs (shown in dark turquoise), cDC1s (brown), cDC2s (orange), slanDCs (red). Each graph shows
the overlay of the stained sample (colored) and the appropriate FMO control (shown in empty gray). A representative analysis is shown.
was not considered, as this subset was undetectable in WB
samples. A representative analysis is shown in Figure 2. By using
this strategy, we observed that the expression of the costimulatory
molecules, expressed as net MFI, was quite variable among DC
subsets, as shown in Figure 3A. According to previous reports,
CD80 expression in basal conditions was negligible in all subsets,
and the expression of CD40 and CD86 was lower on pDCs
than on cDC subsets (36, 42). Besides these expected results, by
directly comparing cDC1s and cDC2s, our immunophenotypic
analysis indicated that cDC1s expressed higher levels of CD40
and lower levels of CD86 than cDC2s. Moreover, according to
their inflammatory function, slanDCs expressed higher CD40
and CD86 levels than cDC2s. As shown in Figure 3B, also the
expression of the inhibitory molecules PD-L1, ILT2, and TIM-3
was quite variable among DC subsets. PD-L1 was expressed at
low levels on slanDCs and was negligible in all other subsets.
ILT2 was expressed in basal conditions on pDCs and cDC2s,
its expression was higher on slanDCs, and negligible on cDC1s.
On the contrary, TIM-3 was expressed at the highest levels
on cDC1s.
Expression of Costimulatory Molecules on
DC Subsets From Healthy Donors Upon
Exposure to Pro-inflammatory and
Anti-inflammatory Stimuli
The ability of DC subsets to undergo TLR-induced activation
was assessed upon exposure to LPS and IMQ, as they had
been previously identified as the best TLR-ligands to be used
in WB assay (28). The activation state of pDCs, cDC1s, cDC2s,
and slanDCs was assessed as cell surface expression of the
costimulatory molecules CD40, CD80, and CD86, using the same
strategy described for the immunophenotypic characterization of
DC subsets in unstimulated conditions. In order to challenge DC
subsets with pro-inflammatory and anti-inflammatory stimuli,
WB samples were incubated in the absence or presence of LPS,
IMQ and IL-10, either alone or in combination. As shown
in Figure 4, stimulation of WB samples with the TLR4-ligand
LPS induced full activation of both cDC subsets and slanDCs,
and only marginal activation of pDCs. Stimulation of WB
samples with the TLR7-ligand IMQ induced the highest CD40
upregulation in pDCs, but also activated cDC subsets and
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FIGURE 3 | Surface expression of costimulatory and inhibitory molecules on DC subsets in basal conditions. The expression levels of the costimulatory molecules
CD40, CD80, CD86 (A) and the inhibitory molecules PD-L1, ILT2, TIM-3 (B) were assessed on pDCs, cDC1s, cDC2s, and slanDCs, and expressed as net MFI. Data
were obtained from 16 healthy donors. Each symbol represents a single sample. In each series, the mean ± SEM is also shown. *p < 0.05, **p < 0.01, ***p < 0.001
vs. pDCs. ###p < 0.001 vs. cDC1s. ◦p < 0.05, ◦◦p < 0.01, ◦◦◦p < 0.001 vs. cDC2s. Statistical significance calculated using the paired t-test.
slanDCs. This lack of selectivity of TLR ligands on either DC
subset when stimulating WB samples is in accordance with our
previous observations, and likely mediated by indirect cytokine-
mediated effects related to the presence of mixed populations
(28). Notably, upon stimulation with either LPS or IMQ, a higher
upregulation of CD80 and CD86 was observed in cDC2s than
cDC1s (p < 0.001 in all cases). Moreover, the upregulation of
costimulatory molecules induced by LPS and IMQ was partially
reverted by the anti-inflammatory cytokine IL-10, that scarcely
affected the expression of costimulatory molecules on any DC
subsets when administered alone.
Expression of Inhibitory Molecules on DC
Subsets From Healthy Donors Upon
Exposure to Pro-Inflammatory and
Anti-inflammatory Stimuli
In order to investigate the ability of the above mentioned DC
subsets to change their surface expression of inhibitory molecules
upon exposure to pro-inflammatory and anti-inflammatory
conditions, in the same samples incubated with LPS, IMQ and IL-
10, and analyzed for the expression of costimulatory molecules,
we also analyzed the expression of the inhibitory molecules PD-
L1, ILT2, and TIM-3. As shown in Figure 5, incubation of WB
samples with TLR-ligands induced an overall upregulation of
the immune checkpoints PD-L1 and ILT2 on DCs, suggesting
that upregulation of these inhibitory molecules during DC
stimulation may represent a mechanism aimed at preventing
the activation of excessive immune responses. According to the
loss of selectivity of TLR-ligands during WB stimulation, both
LPS and IMQ affected the expression of inhibitory molecules
on pDCs and cDCs, although to a different extent. Within cDC
subsets, exposure to TLR-ligands induced a higher upregulation
of PD-L1 on cDC2s than cDC1s (p < 0.0001 in both cases),
and increased the expression of ILT2 on cDC2s only. Consistent
with its immunosuppressive role, IL-10 added during LPS or
IMQ stimulation further increased PD-L1 and ILT2 expression
in most cases, though it was scarcely effective when administered
alone. Finally, the expression of TIM-3 on DC subsets was poorly
affected by WB exposure to TLR-ligands and/or IL-10, as it
maintained its highest expression on cDC1s, a lower expression
on cDC2s and slanDCs, and its lowest expression on pDCs,
whatever the stimulatory conditions were.
Characterization of Peripheral Blood DC
Alterations in MDS Patients by Applying
the New Flow Cytometric Panel
In order to test the newly developed panel on the characterization
of DCs in a pathologic context, we applied our 18-color
method to the study of peripheral blood DCs in patients with
MDS, and compared the results with DC features observed
in healthy donors. As shown in Figure 6A, all circulating
DC subsets, namely pDCs, cDC1s, cDC2s, and slanDCs, were
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FIGURE 4 | Surface expression of costimulatory molecules on DC subsets upon exposure to pro-inflammatory and anti-inflammatory stimuli. The expression of
CD40, CD80, and CD86 was assessed on DCs after 5-h incubation of whole blood samples in the absence or presence of LPS, IMQ, and IL-10 either alone or in
combination. The expression level of each costimulatory molecule was expressed as net MFI. Color legend for DC subsets as reported in legend to Figure 3. Data
were obtained from 16 healthy donors. *p < 0.05, **p < 0.01, ***p < 0.001 vs. basal. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. cells treated with TLR-ligand only.
Statistical significance calculated using the paired t-test.
significantly reduced in the blood of MDS patients compared
with controls. The reduction of DC subsets was not correlated
with disease severity, as the frequency of DC subsets did not
differ between patients with low IPSS or IPSS-R risk score,
and patients with higher scores. Because of DC reduction, the
analysis of costimulatory and checkpoint molecule expression
on cDC1s and slanDCs in MDS patients was hampered by
the low number of cells. Therefore, the immunophenotypic
characterization in these patients was performed only on
pDCs and cDC2s. As shown in Figure 6B, in unstimulated
conditions both subsets tended to be more activated, with a
significantly higher expression of CD86 on MDS than control
cDC2s. The same cells also showed a higher expression of the
inhibitory molecule ILT2. We further investigated the ability
of DCs from MDS patients to change their surface expression
of costimulatory and inhibitory molecules upon exposure to
LPS, IMQ and IL-10, alone or in combination. As shown in
Figure 6C, similar to control DCs, both pDCs and cDC2s
underwent upregulation of CD40, CD80, and CD86 upon
stimulation with LPS and IMQ that was partially reverted
by addition of IL-10. Notably, TLR-induced fold change in
costimulatory molecule expression was significantly lower in
MDS than control DCs, indicating that DCs from MDS patients
were hyporesponsive to TLR stimulation. As shown in the
same figure, similar results were observed when the expression
of inhibitory checkpoints was analyzed. No correlation was
observed between the grade of TLR hyporesponsiveness and
disease severity.
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FIGURE 5 | Surface expression of immune checkpoints on DC subsets upon exposure to pro-inflammatory and anti-inflammatory stimuli. The expression of PD-L1,
ILT2, and TIM-3 was assessed on DCs after 5-h incubation of whole blood samples in the absence or presence of LPS, IMQ, and IL-10 either alone or in combination.
The expression level of each inhibitory molecule was expressed as net MFI. Color legend for DC subsets as reported in legend to Figure 3. Data were obtained from
16 healthy donors. *p < 0.05, **p < 0.01, ***p < 0.001 vs. basal. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. cells treated with TLR-ligand only. Statistical significance
calculated using the paired t-test.
tSNE Analysis Reveals Changes in cDC1s
From MDS Patients and Heterogeneity of
cDC2s Upon TLR-Mediated Stimulation
In order to perform a multidimensional analysis, we further
analyzed our flow cytometric data by using unsupervised tSNE
algorithm. Live CD45+/lin−/HLA-DR+ cells obtained from all
unstimulated and stimulated samples of healthy donors andMDS
patients were concatenated and displayed in a single tSNE dot
plot. Figure 7A showsDC subsets obtained from all unstimulated
and stimulated samples of 16 healthy donors compared with
10 MDS patients. As shown in the Figure, pDCs (shown in
dark turquoise), cDC2s (orange), and slanDCs (red) obtained
from patients fell in the same tSNE regions as healthy donors.
On the contrary, cDC1s (brown) of MDS patients fell in a
tSNE region different from that of control cDC1s, suggesting
the existence of profound differences between these two cell
populations. In order to investigate this issue, we compared
the immunophenotype of cDC1s obtained from patients and
controls. Because of the severe reduction of this cell subset in
the patients’ blood, the analysis was performed on concatenated
files of all unstimulated samples. As shown in Figure 7B, cDC1s
of MDS patients were characterized by higher expression of
CD141 and CD86 than healthy donors. Notably, cDC1s of MDS
patients also showed a huge upregulation of ILT2 expression to
levels even higher than control cDC2s, and a downregulation of
TIM-3 expression to levels similar to control cDC2s, indicating
an overall subversion of the immune checkpoint repertoire of
cDC1s in MDS patients. Finally, in order to assess the impact
of stimulation on DC geographical location in tSNE plots, we
compared tSNE plots showing DC subsets obtained in each single
culture condition. As shown in Figure 7C, unlike the other DC
subsets that maintained the same position in the tSNE plot
regardless of the culture conditions, upon stimulation cDC2s
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FIGURE 6 | Characterization of peripheral blood DC alterations in MDS patients. (A) The frequency of DC subsets in whole blood samples obtained from healthy
donors (full circles, n = 16) and MDS patients (empty circles, n = 10), was expressed as percentage of mononuclear cells. (B) The expression levels of the
costimulatory molecules CD40, CD80, CD86 and the inhibitory molecules PD-L1, ILT2, TIM-3 were assessed on pDCs and cDC2s of healthy donors (gray bars) and
MDS patients (white bars behind colored empty circles) and expressed as net MFI. In each series, the mean ± SEM is also shown. *p < 0.05, **p < 0.01, ***p <
0.001 vs. healthy controls. Statistical significance calculated using the t-test. (C) Surface expression of costimulatory molecules and immune checkpoints on pDCs
and cDC2s upon exposure to pro-inflammatory and anti-inflammatory stimuli in healthy controls (mean shown as gray line, n = 16) and MDS patients (colored lines,
each line corresponding to one patient, n = 10). The expression of CD40, CD80, CD86, PD-L1, ILT2, and TIM-3 was assessed on DCs after 5-h incubation of whole
blood samples in the absence or presence of LPS, IMQ, and IL-10 either alone or in combination. The expression level of each analyzed molecule was expressed as
fold change of the net MFI normalized on untreated sample (Basal). §p < 0.05, §§p < 0.01, §§§p < 0.001 MDS vs. healthy controls. Statistical significance calculated
using the t-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs. MDS basal. #p < 0.05, ##p < 0.01 vs. MDS cells treated with TLR-ligand only. Statistical significance
calculated using the paired t-test.
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clusterized into three different regions that did not overlap with
the region of unstimulated cDC2s. This finding may suggest
that, upon TLR-induced stimulation, cDC2s underwent more
profound changes compared with the other DC subsets analyzed.
However, the comparison of concatenated files obtained from the
three clusters of stimulated cDC2s failed to highlight substantial
differences among clusters; the comparison of these clusters
with the cluster of unstimulated cDC2s did not demonstrate
additional differences between unstimulated and stimulated
clusters, beyond the obvious parameters already described by the
analysis of each single tube.
DISCUSSION
In this study, we investigated the differential expression of
major activatory and inhibitory molecules on peripheral blood
DC subsets, in basal conditions and upon in vitro exposure
to inflammatory and anti-inflammatory stimuli. To this aim,
we developed a 18-color flow cytometry panel dedicated to the
immunophenotypic characterization of DC subsets. By applying
this panel to the analysis of whole blood samples obtained from
healthy donors, on the one hand we could confirm some previous
observations, thus providing evidence for assay reliability; on
the other hand, we observed important differences in the
expression of activatory and inhibitory molecules among DC
subsets, that may bring novel insights into the comprehension
of DC heterogeneity.
In particular, by directly comparing the two cDC subsets, we
observed that in basal conditions cDC1s are characterized by
higher CD40 and lower CD86 expression than cDC2s. Similar
results were reported in a previous study investigating the
expression of costimulatory molecules on cDC subsets (42), but
were not confirmed in other studies (39, 43, 44). Although
we do not have evident explanations for these discrepancies,
our observation that the difference in CD86 expression was
maintained upon TLR-mediated stimulation, together with the
knowledge that CD40 and CD86 play different roles in immune
activation (45, 46), may strengthen the relevance of our finding
and suggest a potential contribution of these molecules to the
functional specialization of DC subsets that may deserve further
investigation in future studies.
Moreover, in this study we observed a great variability among
DC subsets in the expression of the checkpoint molecules PD-
L1, ILT2, and TIM-3. This observation may be particularly
relevant in view of the increasing interest in understanding
the role played by DCs during immune checkpoint blockade
in cancer immunotherapy. In fact, remarkable and long-term
responses to these treatments are achieved only in a proportion of
patients (23). Understanding the reasons for patient variability in
response to therapy and developing reliable biomarkers to predict
patients who are likely to respond to checkpoint inhibitors
remains a challenge. In the case of PD-1/PD-L1 blockade, PD-
L1 is a ligand of the co-inhibitory receptor programmed death-
1 (PD-1) that is expressed on activated T cells and that, if
engaged by its ligands, suppresses T cell function primarily by
inactivating CD28 signaling (47). Because many tumors express
PD-L1, the rationale of PD-L1 pathway blockade is to inhibit
the immunosuppressive PD-L1/PD-1 interaction between tumor
cells and T cells that hampers the activity of CD4+ and CD8+ T
cells (48). Accordingly, the expression of PD-L1 on tumor cells
has been used as a predictive biomarker of treatment response
in many studies [reviewed in (24)]. However, positive responses
to PD-1/PD-L1 blockade are often observed in patients whose
tumor cells lack PD-L1 expression, suggesting that additional
mechanisms may contribute to treatment efficacy (48). Indeed,
a positive response to anti-PD-L1 therapy has been associated
with high expression of PD-L1 on tumor-infiltrating immune
cells across multiple cancer types, indicating a role for PD-
L1+ immune cells in suppressing anti-tumor responses, which
are re-invigorated on blockade of PD-L1 signaling (49). PD-
L1+ DCs may contribute to the immunosuppressive tumor
microenvironment not only by suppressing the activity of T
cells, as demonstrated in many preclinical models [reviewed in
(48, 50)], but also by promoting the expansion of regulatory
T cells (51) and establishing immunoregulatory interactions
with NK cells and other immune cells (50). According to
DC heterogeneity, it is possible that the regulation of PD-L1
expression and the effects of PD-L1+ DCs may differ among
different DC subsets. Indeed, the results of our study seem to
support this hypothesis. In fact, consistent with previous studies
investigating PD-L1 expression in different experimental models
(52–55), we observed that PD-L1 was almost undetectable on
all subsets of DC-lineage DCs in basal conditions, and it
was significantly upregulated on all subsets upon TLR-driven
stimulation. However, the levels of PD-L1 induced by incubation
with LPS and IMQ were quite variable among DC subsets, with
the highest levels observed on slanDCs and the lowest levels on
cDC1s. The in vivo relevance of this finding will deserve further
investigation, by analyzing PD-L1 expression on the different
DC subsets at the tissue level. In particular, relevant to the use
of PD-1/PD-L1 inhibitors in cancer immunoherapy, it will be
interesting to verify the differential expression of PD-L1 on DC
subsets in the tumormicroenvironment, whichmay contribute to
PD-L1 upregulation on DCs through the action of various factors
including IL-10, as used in our study, and tumor growth factor
(TGF)-β (56).
Another interesting result of our study was the demonstration
that cDC1s failed to express ILT2, both in unstimulated and TLR-
stimulated conditions, while all the other DC subsets showed
a basal expression of ILT2 that was further upregulated upon
exposure to LPS and IMQ. ILT2 is another important checkpoint,
expressed on the surface of various immune cell types. It binds
classical and non-classical MHC class I molecules with a higher
affinity for HLA-G (57) and, upon interaction with its ligands, it
inhibits cell function through ITIM signaling (58). The relevance
of the inhibitory role of ILT2 in DCs is supported by the
demonstration that ILT2 is upregulated on human tolerogenic
DCs differentiated in vitro using different agents (59, 60), and
it is diminished on peripheral blood DCs of patients with
autoimmune diseases (61). As the regulation of ILT2 expression
on DCs has been poorly investigated so far, our observation
that ILT2 levels are increased on most DC subsets upon TLR-
stimulation is interesting and may suggest that, similarly to
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FIGURE 7 | tSNE plots showing the clustering of peripheral blood DC subsets in healthy donors and MDS patients. Live CD45+/lin−/HLA-DR+ cells obtained from all
unstimulated and stimulated samples of healthy donors (n = 16) and MDS patients (n = 10) were concatenated and displayed in a single tSNE dot plot (shown in
gray). (A) tSNE plots showing clustered DC subsets in pooled unstimulated and stimulated samples of healthy controls (upper plot) compared with MDS patients
(lower plot). Color code as indicated. Note the different geographic location of cDC1s in patients and controls. (B) The expression of CD141, costimulatory molecules
(CD40, CD80, CD86), and immune checkpoints (PD-L1, ILT2, and TIM-3) was assessed on cDC1s from healthy donors (gray bars) and MDS patients (brown bars).
Data expressed as MFI measured on concatenated files from all unstimulated samples. (C) tSNE plots showing clustered DC subsets in each single culture condition,
in controls (left column) and MDS patients (right column). Note the different geographical location of unstimulated and TLR-stimulated cDC2s.
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PD-L1, ILT2 is upregulated on DCs upon pathogen-driven
stimulation in order to prevent excessive T cell activation and
avoid uncontrolled inflammation. Notably, the complete lack
of ILT2 expression on cDC1s, together with the lower PD-L1
expression on these cells, may suggest that cDC1s are regulated
by different checkpoints compared with the other DC subsets.
Indeed, we observed that, compared with the other DC
populations, cDC1s expressed remarkably higher levels of TIM-
3, an immune checkpoint that upon interaction with the nuclear
protein HMGB1 limits the release of pro-inflammatory cytokines
by DCs, thus weakening type I responses (62). Interestingly,
consistent with the superior ability of cDC1s to cross-present
antigens and activate cytotoxic T cell responses, TIM-3 also
binds phosphatidylserine and through this interaction it favors
DC capture of apoptotic cells and cross-presentation (63), thus
suggesting that the higher expression of TIM-3 on cDC1s may
be coeherent with the functional specialization of this DC subset.
Notably, a high expression of TIM-3 on the murine equivalent of
human cDC1s has been recently described (64), and an important
role of TIM-3 expression on these cells has been suggested
by the observation that, in a murine model of breast cancer,
treatment with TIM-3-blocking antibody increased the immune-
mediated response to therapy through cDC1-dependent, not
yet clarified mechanisms (64). In addition, TIM-3 expression is
increased on tumor-associated DCs in various human cancers
(62, 64). The emerging scenario may be, therefore, that cDC1s,
though necessary for anti-cancer immunity, are tamed by the
immunosuppressive tumor microenvironment through TIM-
3 upregulation, that in turn regulates DC function. In this
respect, it is worthy noting that in our study IL-10 alone was
insufficient to upregulate TIM-3 expression, suggesting that
multiple components of the tumormicroenvironment are needed
for taming DCs with TIM-3.
Indeed, the results obtained in this study by analyzing
peripheral blood DCs in MDS patients suggest the possibility of
another, unforeseen, scenario. In fact, we observed a significant
decrease of all DC subsets, and this finding is in line with previous
studies reporting a reduction of cDCs and pDCs in the blood
and bone marrow of MDS patients (65, 66). We also observed
an overall activation of cDC2s, and a hyporesponsiveness of
pDCs and cDC2s to TLR-mediated stimulation. These findings
may likely reflect the chronic hyperactivation of TLRs occurring
in MDS (67), and the subsequent desensitization of DCs
to further TLR-induced stimulation (68, 69). But the most
striking result of our study was the observation that cDC1s
from MDS patients undergo profound changes, resulting in
their falling in a different tSNE region compared with cDC1s
from healthy donors. Relevant to the above considerations on
immune checkpoints, cDC1s from MDS patients showed huge
upregulation of ILT2 and downregulation of TIM-3 expression,
thus denoting an overall subversion of their inhibitory molecule
repertoire. Further studies will be needed in order to investigate
whether these cDC1 changes are also present in the bone marrow
of MDS patients, whether they are sustained by the neoplastic
process or they play a causative role in it, whether they are related
to the immune dysregulation occurring in MDS (67), or whether
they are shared with other pathologic conditions where DCs play
a crucial role, including other types of cancer, infections, chronic
inflammatory diseases. Further studies on sorted DC subsets will
also be needed in order to investigate the molecular mechanisms
underlying these cDC1 changes, and the impact of these changes
on DC function.
In conclusion, in this study we developed a flow cytometry
panel that allows a direct comparison of the activatory/regulatory
phenotype of DC-lineage and inflammatory DC subsets. By
applying this panel to the study of DCs in the peripheral
blood, we demonstrated that functionally distinct DC subsets
are characterized by differential expression of activatory
and inhibitory molecules, and that cDC1s in particular
are endowed with a unique immune checkpoint repertoire
characterized by high expression of TIM-3 and scarce or null
expression of PD-L1 and ILT2, respectively, suggesting that
differential mechanisms are used by different DC subsets
to control immune responses. The observation that the
immune checkpoint repertoire of cDC1s is subverted in MDS
patients may pave the way for understanding the impact
of these molecules on DC function. Applied to the study
of DCs in the tumor microenvironment, this panel has the
potential to provide valuable information to be used for
improving our comprehension of the role of distinct DC
subsets in cancer, guiding DC-targeting immunotherapy,
and possibly identifying predictive biomarkers for clinical
response in cancer patients undergoing immune checkpoint
blockade treatment.
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